| [Fire Fighting] Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire. | |
| [Ingestion] Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended. | |
| [Inhalation] If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention. | |
| [Skin] Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes. | |
| [Eyes] If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention. | |
| [Storage] Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage. | |
| [Handling] All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood. | |
| [Inhalation] Tachypnea occurred in a patient with neuroleptic malignant syndrome previously exposed to other neuroleptics. | |
| [Ingestion] Dry mouth, contributing to dysphagia, has been reported during molindone therapy. Weight gain and loss during therapeutic use have occurred. | |
| [Personal Protection] Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots. | |
| [Respirators] Use NIOSH/MSHA approved respirator appropriate for exposure of concern. | |
| [Exposure Effects] Hyperpyrexia, abnormally low blood pressure and shallow, rapid respirations have occurred with therapeutic use in patients previously exposed to neuroleptics. neuroleptic malignant syndrome (symptoms include: fever, rigidity, autonomic instability, altered mental status, rhabdomyolysis and diaphoresis) has been reported in one therapeutically dosed patient previously exposed to neuroleptics. Extrapyramidal effects (rigidity, tremor, akathisia, major tonic spasms and tardive dyskinesia) have been reported with therapeutic use and may occur in overdose. | |
| [Appearance] Crystals. | |
| [Solubility in water] Insoluble | |
| [Melting Point] 180 - 181 | |
| [pKa/pKb] 6.83 (pKa) | |
| [Usage] Medication. | |
| [Product Name] 3-Ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one | |
| [Synonyms] (+/-)-Molindone 3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-4H-indol-4-one 3-Ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one 3-Ethyl-6,7-dihydro-2-methyl-5-(morpholinomethyl)indol-4(5H)-one | |
| [CAS] "CASEN_7416-34-4.htm">7416-34-4 | |
| [Formula] C16H24N2O2 | |
| [Molecular Weight] 276.38 | |
| [RTECS] NM3300000 | |
| [RTECS Class] Drug; Human Data | |
| [Merck] 12,6315 | |
| [Beilstein/Gmelin] 413239 | |
| [Small spills/leaks] Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces. | |
| [Stability] No data. | |
| [Incompatibilities] Strong oxidizing agents. |
Print